Mentions
Extended reach
Total likes
Video views
AI synopsis
Discussions feature enthusiastic support for the trial results, citing specific data such as 63% disease resolution and 37% fibrosis reduction, and using words like 'big news' and 'promising' to convey excitement and high impact. The tone and emphasis on clinical benefits reflect strong engagement and belief in the trial's significance.
Most discussions strongly support the positive outcomes of the trial, emphasizing benefits and promising results.
Participants show high curiosity, frequently mentioning improvements in liver health, weight loss, and fibrosis reduction.
The posts involve detailed references to trial data, percentages, and clinical implications, indicating deep interest.
The consensus highlights the significance of these findings, with many calling it 'big news' and a potential game-changer for treatment.
Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2S8C Editorial: Semaglutide for Metabolic Dysfunction–Associated Steatohepatitis https://t.co/fQHYZfv2g3 #Endocrinology #Gastroenterology https://t.co/h9h8LynNnk
Aqui les dejo artículo por si quieren leerlo https://t.co/2rJJd7mek8 Miren nada mas esas gráficas. https://t.co/EoYU8jg43l
yet another analysis of KETO-CTA by a medical professional quite good IMHO by @drjohnm https://t.co/MN2B49xK2L
Phase 3 Trial of #Semaglutide in #Metabolic Dysfunction–Associated #Steatohepatitis In patients with #MASH and moderate or advanced #liver #fibrosis, once-weekly semaglutide at a dose of 2.4 mg improved liver steatohepatitis & fibrosis https://t.co/vfcgItgXpb
1/8 ⏰ for #EBGI Tweetorial
1️⃣ ESSENCE trial
This video explores recent research on fatty liver disease, focusing on GLP1 medications, diet, and exercise's role in management, and the importance of ongoing care for sustained health improvements.
Semaglutide is tested as a treatment for metabolic dysfunction-associated steatohepatitis in a phase 3 trial. Results at 72 weeks show significant improvement in liver health and weight loss, highlighting its potential…
This week’s podcast discusses the KETOCTA study and stroke prevention in patients with device-detected atrial fibrillation. Key findings from two significant trials highlight the effectiveness of direct oral…
Semaglutide significantly improves histologic outcomes in patients with metabolic dysfunction-associated steatohepatitis, demonstrating higher rates of disease resolution and fibrosis reduction compared to placebo in a…
This video covers recent updates on MASLD and MASH management. It highlights a phase 3 trial of semaglutide showing significant improvements in steatohepatitis resolution, fibrosis reduction, and weight loss…
Semaglutide shows promising results in treating metabolic-associated steatohepatitis, with significant improvements in liver health and weight loss. Long-term efficacy could make it a key therapeutic tool in hepatology.
1/8 ⏰ for #EBGI Tweetorial
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis https://t.co/7KzCVkt1GF https://t.co/7OSzOY9xnw
RT @sociedadSEEN:
RT @sociedadSEEN:
RT @sociedadSEEN:
RT @sociedadSEEN:
RT @EricTopol: Another win for semaglutide (Ozempic) and the GLP-1 drugs: reduction of liver fibrosis in MASH https://t.co/y01wIw5nIs
RT @EricTopol: Another win for semaglutide (Ozempic) and the GLP-1 drugs: reduction of liver fibrosis in MASH https://t.co/y01wIw5nIs
A Phase 3 trial of semaglutide (2.4 mg weekly) in MASH patients showed: - 63% achieved disease resolution (vs 34% placebo) - 37% saw fibrosis reduction (vs 22% placebo) - 10.5% avg weight loss - Main side effect: GI issues https://t.co/95R48XaVXX https://t.co/0vOlHzXACH
Además de sus conocidos beneficios (reducción de peso, niveles de azúcar, presión arterial y lípidos), la semaglutida también redujo la inflamación y la fibrosis en pacientes con MASH https://t.co/ZJmTXL6ZhV https://t.co/QPQY3hCIcY
The primary end points for part 1 were the resolution of steatohepatitis without worsening of liver fibrosis and reduction in liver fibrosis without worsening of steatohepatitis. https://t.co/6vhoziWxhy
RT @moy_qmac: Aqui les dejo artículo por si quieren leerlo https://t.co/2rJJd7mek8 Miren nada mas esas gráficas. https://t.co/EoYU8jg43l
RT @DrSamuelBHume: Sources: 1. Semaglutide FDA-approved for MASH - approval (https://t.co/G64yQGLH8b) and trial (https://t.co/hHZdjEW3iw)…
Sources: 1. Semaglutide FDA-approved for MASH - approval (https://t.co/G64yQGLH8b) and trial (https://t.co/hHZdjEW3iw) 2. Teplizumab approved in the UK to delay type 1 diabetes - approval (https://t.co/D3mKWK5aCP) and trial (https://t.co/brFJLfRhRd) 3. Brensocatib
RT @moy_qmac: Aqui les dejo artículo por si quieren leerlo https://t.co/2rJJd7mek8 Miren nada mas esas gráficas. https://t.co/EoYU8jg43l
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine https://t.co/vEzO2Y1hyj
RT @moy_qmac: Aqui les dejo artículo por si quieren leerlo https://t.co/2rJJd7mek8 Miren nada mas esas gráficas. https://t.co/EoYU8jg43l
RT @moy_qmac: Aqui les dejo artículo por si quieren leerlo https://t.co/2rJJd7mek8 Miren nada mas esas gráficas. https://t.co/EoYU8jg43l
【備忘】 米国FDAはセマグルチド注射剤の適応にMASHを追加。RCT “ESSENCE”[https://t.co/W3HfH1nLEY] の結果を受け。 製造社リリース https://t.co/KsCN4UVGnR
RT @moy_qmac: Aqui les dejo artículo por si quieren leerlo https://t.co/2rJJd7mek8 Miren nada mas esas gráficas. https://t.co/EoYU8jg43l
RT @moy_qmac: Aqui les dejo artículo por si quieren leerlo https://t.co/2rJJd7mek8 Miren nada mas esas gráficas. https://t.co/EoYU8jg43l
RT @moy_qmac: Aqui les dejo artículo por si quieren leerlo https://t.co/2rJJd7mek8 Miren nada mas esas gráficas. https://t.co/EoYU8jg43l
RT @moy_qmac: Aqui les dejo artículo por si quieren leerlo https://t.co/2rJJd7mek8 Miren nada mas esas gráficas. https://t.co/EoYU8jg43l
RT @moy_qmac: Aqui les dejo artículo por si quieren leerlo https://t.co/2rJJd7mek8 Miren nada mas esas gráficas. https://t.co/EoYU8jg43l
RT @moy_qmac: Aqui les dejo artículo por si quieren leerlo https://t.co/2rJJd7mek8 Miren nada mas esas gráficas. https://t.co/EoYU8jg43l
RT @moy_qmac: Aqui les dejo artículo por si quieren leerlo https://t.co/2rJJd7mek8 Miren nada mas esas gráficas. https://t.co/EoYU8jg43l
RT @hvanspall: FDA announces approval for #semaglutide 2.4 mg sc weekly for #MASLD based on results of the #ESSENCE #RCT. Did you know tha…
Muchos medicos se la han pasado alabando este estudio de la semaglutida (ozempic) en pacientes con fibrosis o hígado graso. https://t.co/C5j9SqXrh2
Aqui les dejo artículo por si quieren leerlo https://t.co/2rJJd7mek8 Miren nada mas esas gráficas. https://t.co/EoYU8jg43l
RT @hvanspall: FDA announces approval for #semaglutide 2.4 mg sc weekly for #MASLD based on results of the #ESSENCE #RCT. Did you know tha…
RT @hvanspall: FDA announces approval for #semaglutide 2.4 mg sc weekly for #MASLD based on results of the #ESSENCE #RCT. Did you know tha…
رابط الدراسة : https://t.co/qylvThyW5I https://t.co/UensGNaf4T
RT @hvanspall: FDA announces approval for #semaglutide 2.4 mg sc weekly for #MASLD based on results of the #ESSENCE #RCT. Did you know tha…
RT @hvanspall: FDA announces approval for #semaglutide 2.4 mg sc weekly for #MASLD based on results of the #ESSENCE #RCT. Did you know tha…
خبر مهم في مجال أمراض الكبد والتمثيل الغذائي وافقت إدارة الغذاء والدواء الأمريكية (FDA) على دواء Wegovy (سيماجلوتايد) كأول علاج لـ مرض التهاب الكبد الدهني المرتبط بخلل التمثيل الغذائي (MASH)، مما يمثل اختراقًا كبيرًا لمرضى هذا الاضطراب الكبدي الخطير. https://t.co/kcLJciOVtE
خبر مهم في مجال أمراض الكبد والتمثيل الغذائي وافقت إدارة الغذاء والدواء الأمريكية (FDA) على دواء Wegovy (سيماجلوتايد) كأول علاج لـ مرض التهاب الكبد الدهني المرتبط بخلل التمثيل الغذائي (MASH)، مما يمثل اختراقًا كبيرًا لمرضى هذا الاضطراب الكبدي الخطير. https://t.co/kcLJciOnE6
RT @hvanspall: FDA announces approval for #semaglutide 2.4 mg sc weekly for #MASLD based on results of the #ESSENCE #RCT. Did you know tha…
FDA announces approval for #semaglutide 2.4 mg sc weekly for #MASLD based on results of the #ESSENCE #RCT. Did you know that #CVD is the leading cause of death in patients with #MASLD? Common mechanisms & now, common treatments for #CKLM diseases https://t.co/vfcgItgXpb https://t.co/jHa8d8vmQ5 https://t.co/e2GNOvfaBg
RT @CristobMorales: https://t.co/PpebEUukvq “In patients with MASH and moderate or advanced liver fibrosis, once-weekly #semaglutide at a d…
RT @CristobMorales: https://t.co/PpebEUukvq “In patients with MASH and moderate or advanced liver fibrosis, once-weekly #semaglutide at a d…
RT @CristobMorales: https://t.co/PpebEUukvq “In patients with MASH and moderate or advanced liver fibrosis, once-weekly #semaglutide at a d…
RT @ebtapper: Semaglutide improved inflammation and fibrosis in people with MASH / NASH 1. Generalizable gem: 10% body weight loss is the…
RT @CMEINDIA1: Semaglutide in MASH:Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis ESSENCE of MASH Therapy…
RT @CMEINDIA1: Semaglutide in MASH:Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis ESSENCE of MASH Therapy…
RT @Dr_Ampuero: 1️⃣ ESSENCE trial
RT @Dr_Ampuero: 1️⃣ ESSENCE trial
RT @Dr_Ampuero: 1️⃣ ESSENCE trial
RT @Dr_Ampuero: 1️⃣ ESSENCE trial
RT @Dr_Ampuero: 1️⃣ ESSENCE trial
RT @Dr_Ampuero: 1️⃣ ESSENCE trial
RT @Dr_Ampuero: 1️⃣ ESSENCE trial
RT @Dr_Ampuero: 1️⃣ ESSENCE trial
RT @Dr_Ampuero: 1️⃣ ESSENCE trial
RT @Dr_Ampuero: 1️⃣ ESSENCE trial
RT @Dr_Ampuero: 1️⃣ ESSENCE trial
1️⃣ ESSENCE trial
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
@drjohnm https://t.co/PkLfRWaIcf
セマグルチドが肝臓病にも効果的 https://t.co/XDDO5QMRr9 セマグルチド（オゼンピック等）が、重篤な脂肪肝疾患MASHに対しても効果を示したよーという研究。72週間の投与で約63%の患者で脂肪肝炎が改善し、37%で肝線維化も軽減。体重も平均10.5%減少したとのこと
What we suspected but now confirmed ....Improvement in fibrosis with semaglutide! Does this change your management? Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine https://t.co/Bdh5qK0XP5
Semaglutide significantly improved liver health in patients with metabolic dysfunction-associated steatohepatitis, outperforming placebo in key outcomes. by Sanyal AJ, Newsome PN (...) Ratziu V et 8 al. in N Engl J Med https://t.co/NRlO9UWOXR #MedX #MedResearch
Full text links https://t.co/LCfw9gf9tN
Bibliografia en @PubMedOnline Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis Arun J Sanyal et al. N Engl J Med. 2025. https://t.co/SYtp23yYn1 https://t.co/DYlMBuVl9C
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
@rolleig sin olvidar el "hepato" https://t.co/71mDddHTCZ
RT @drleonjimenez: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine https…
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine https://t.co/fHiRDmnJXt GOOD NEWS¡¡¡ @gt_rcv @Diabetes_SEMI
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
Phase 3 trial: 1197 patients with MASH, fibrosis stage 2/3, random 2:1 semaglutide 2.4 mg/placebo, 72-week interim shows promising results! PMID:40305708, N Engl J Med 2025, @NEJM https://doi.org/10.1056/NEJMoa2413258 #Medsky #Pharmsky #RNA #ASHG #ESHG
Phase 3 trial: 1197 patients with MASH, fibrosis stage 2/3, random 2:1 semaglutide 2.4 mg/placebo, 72-week interim shows promising results! PMID:40305708, N Engl J Med 2025, @NEJM https://t.co/A09ORKBoGd #AI #Pharma #BioMed #RNA #ASHG #ESHG
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine https://t.co/kFHqf3gnAz
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @drbennisahmed: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis In patients with MASH and moderate or…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis In patients with MASH and moderate or advanced liver fibrosis, once-weekly semaglutide at a dose of 2.4 mg improved liver histologic results https://t.co/75siyGR2xS https://t.co/wpy2DBVUcE
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine https://t.co/CDVZrG5CXJ #health #Medicine #weightloss #healthcare
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: In an interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-week…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: In an interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-week…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @kamleshkhunti: ESSENCE Trial @NEJM Significant benefits of semaglutide in people with MASH and moderate or advanced liver fibrosis,…
RT @NEJM: In an interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-week…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
"...we found evidence for the superiority of semaglutide over placebo for histologic reductions in steatohepatitis and fibrosis." https://t.co/1Q5z30qybA
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2…
Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/8zxann2S8C Editorial: Semaglutide for Metabolic Dysfunction–Associated Steatohepatitis https://t.co/fQHYZfv2g3 #Endocrinology #Gastroenterology https://t.co/h9h8LynNnk
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine https://t.co/nTTie4KkRT
RT @NEJM: In an interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-week…
RT @NEJM: In an interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-week…
RT @NEJM: In an interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-week…
RT @NEJM: In an interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-week…
RT @NEJM: In an interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-week…
RT @NEJM: In an interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-week…
RT @NEJM: In an interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-week…
RT @NEJM: In an interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-week…
Phase 3 Trial of #Semaglutide in #Metabolic Dysfunction–Associated #Steatohepatitis In patients with #MASH and moderate or advanced #liver #fibrosis, once-weekly semaglutide at a dose of 2.4 mg improved liver steatohepatitis & fibrosis at 72 weeks t.co/vfcgItgXpb
RT @NEJM: In an interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-week…
RT @NEJM: In an interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-week…
RT @NEJM: In an interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-week…
RT @hvanspall: Phase 3 Trial of #Semaglutide in #Metabolic Dysfunction–Associated #Steatohepatitis In patients with #MASH and moderate or…
RT @NEJM: In an interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-week…
RT @NEJM: In an interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-week…
RT @NEJM: In an interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-week…
RT @NEJM: In an interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-week…
RT @NEJM: In an interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-week…
RT @hvanspall: Phase 3 Trial of #Semaglutide in #Metabolic Dysfunction–Associated #Steatohepatitis In patients with #MASH and moderate or…
RT @hvanspall: Phase 3 Trial of #Semaglutide in #Metabolic Dysfunction–Associated #Steatohepatitis In patients with #MASH and moderate or…
RT @hvanspall: Phase 3 Trial of #Semaglutide in #Metabolic Dysfunction–Associated #Steatohepatitis In patients with #MASH and moderate or…
RT @hvanspall: Phase 3 Trial of #Semaglutide in #Metabolic Dysfunction–Associated #Steatohepatitis In patients with #MASH and moderate or…
RT @hvanspall: Phase 3 Trial of #Semaglutide in #Metabolic Dysfunction–Associated #Steatohepatitis In patients with #MASH and moderate or…
In an interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-weekly semaglutide improved liver histologic results at 72 weeks. Full ESSENCE trial results and Research Summary: nej.md/3EVFAFM #MedSky #EndoSky #GastroSky
RT @hvanspall: Phase 3 Trial of #Semaglutide in #Metabolic Dysfunction–Associated #Steatohepatitis In patients with #MASH and moderate or…
RT @hvanspall: Phase 3 Trial of #Semaglutide in #Metabolic Dysfunction–Associated #Steatohepatitis In patients with #MASH and moderate or…
【RCT】肝線維化ステージ2または3の代謝機能障害関連脂肪肝炎患者へのセマグルチドの投与は、プラセボの投与と比較して、肝繊維化の悪化なしでの脂肪肝炎の解決および脂肪肝炎悪化なしでの肝繊維症の改善を増加させた。 #ペ読 https://t.co/yVNRfSyk5s
RT @hvanspall: Phase 3 Trial of #Semaglutide in #Metabolic Dysfunction–Associated #Steatohepatitis In patients with #MASH and moderate or…
RT @hvanspall: Phase 3 Trial of #Semaglutide in #Metabolic Dysfunction–Associated #Steatohepatitis In patients with #MASH and moderate or…
RT @hvanspall: Phase 3 Trial of #Semaglutide in #Metabolic Dysfunction–Associated #Steatohepatitis In patients with #MASH and moderate or…
RT @hvanspall: Phase 3 Trial of #Semaglutide in #Metabolic Dysfunction–Associated #Steatohepatitis In patients with #MASH and moderate or…
RT @hvanspall: Phase 3 Trial of #Semaglutide in #Metabolic Dysfunction–Associated #Steatohepatitis In patients with #MASH and moderate or…
RT @hvanspall: Phase 3 Trial of #Semaglutide in #Metabolic Dysfunction–Associated #Steatohepatitis In patients with #MASH and moderate or…
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine https://t.co/qenI4pK0hn
Phase 3 Trial of #Semaglutide in #Metabolic Dysfunction–Associated #Steatohepatitis In patients with #MASH and moderate or advanced #liver #fibrosis, once-weekly semaglutide at a dose of 2.4 mg improved liver steatohepatitis & fibrosis https://t.co/vfcgItgXpb
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine www.nejm.org/doi/full/10....
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine This is BIG/good news: "In patients with MASH and moderate or advanced liver fibrosis, once-weekly semaglutide at a dose of 2.4 mg improved liver histologic results"
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine https://t.co/7H8gSo0yow
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine https://t.co/xwNBc1qYfp
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine https://t.co/RamFwy55lj
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine www.nejm.org/doi/full/10....
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine https://t.co/EJApmkgvNx
"Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis." Étude ESSENCE, publiée ce jour dans le @nejm.org. #MedSky #LiverSky #GastroSky www.nejm.org/doi/full/10....
RT @drjorfer: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine https://t.co/i3U2FE9QD0
In patients with MASH and moderate or advanced liver fibrosis, once-weekly semaglutide at a dose of 2.4 mg improved liver histologic results. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine https://t.co/XMn8UXiig1
I guess it's a "cure-all"! Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine https://t.co/JcmW6OvIVE
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine
Ensayo en fase 3 de semaglutida en la esteatohepatitis asociada con disfunción metabólica https://t.co/lzg9fNGg2T PMID 40305708
RT @agingdoc1: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis https://t.co/BJpKP5Blg5
RT @agingdoc1: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis https://t.co/BJpKP5Blg5
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis https://t.co/BJpKP5Blg5
View the full story here - ⬇️⬇️⬇️ https://t.co/EzByaDVe0n View the study abstract here - ⬇️⬇️⬇️ https://t.co/5qp8zqqZYj Read other NHD Latest News stories here - ⬇️⬇️⬇️ https://t.co/ItEC3CQ3mh
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis Published April 30, 2025 DOI: 10.1056/NEJMoa24132 https://t.co/qXkNSuKft4
https://t.co/NPgKXUF8oQ
RT @NutritionMadeS3: yet another analysis of KETO-CTA by a medical professional quite good IMHO by @drjohnm https://t.co/MN2B49xK2L
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine @nejm #obesity https://t.co/hEVGTKeq7g
RT @NutritionMadeS3: yet another analysis of KETO-CTA by a medical professional quite good IMHO by @drjohnm https://t.co/MN2B49xK2L
RT @NutritionMadeS3: yet another analysis of KETO-CTA by a medical professional quite good IMHO by @drjohnm https://t.co/MN2B49xK2L
RT @NutritionMadeS3: yet another analysis of KETO-CTA by a medical professional quite good IMHO by @drjohnm https://t.co/MN2B49xK2L
RT @NutritionMadeS3: yet another analysis of KETO-CTA by a medical professional quite good IMHO by @drjohnm https://t.co/MN2B49xK2L
RT @NutritionMadeS3: yet another analysis of KETO-CTA by a medical professional quite good IMHO by @drjohnm https://t.co/MN2B49xK2L
RT @NutritionMadeS3: yet another analysis of KETO-CTA by a medical professional quite good IMHO by @drjohnm https://t.co/MN2B49xK2L
RT @NutritionMadeS3: yet another analysis of KETO-CTA by a medical professional quite good IMHO by @drjohnm https://t.co/MN2B49xK2L
RT @NutritionMadeS3: yet another analysis of KETO-CTA by a medical professional quite good IMHO by @drjohnm https://t.co/MN2B49xK2L
RT @NutritionMadeS3: yet another analysis of KETO-CTA by a medical professional quite good IMHO by @drjohnm https://t.co/MN2B49xK2L
yet another analysis of KETO-CTA by a medical professional quite good IMHO by @drjohnm https://t.co/MN2B49xK2L
Semaglutide significantly improved liver health and reduced body weight in patients with metabolic dysfunction-associated steatohepatitis. by Sanyal AJ, Newsome PN (...) Ratziu V et 8 al. in N Engl J Med #MedSky
Semaglutide significantly improved liver health and reduced body weight in patients with metabolic dysfunction-associated steatohepatitis. by Sanyal AJ, Newsome PN (...) Ratziu V et 8 al. in N Engl J Med https://t.co/NRlO9UWOXR #MedX #MedResearch
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine https://t.co/4tVIFOpX43
RT @kamleshkhunti: ESSENCE Trial @NEJM Significant benefits of semaglutide in people with MASH and moderate or advanced liver fibrosis,…
RT @kamleshkhunti: ESSENCE Trial @NEJM Significant benefits of semaglutide in people with MASH and moderate or advanced liver fibrosis,…
RT @kamleshkhunti: ESSENCE Trial @NEJM Significant benefits of semaglutide in people with MASH and moderate or advanced liver fibrosis,…
RT @kamleshkhunti: ESSENCE Trial @NEJM Significant benefits of semaglutide in people with MASH and moderate or advanced liver fibrosis,…
RT @kamleshkhunti: ESSENCE Trial @NEJM Significant benefits of semaglutide in people with MASH and moderate or advanced liver fibrosis,…
RT @kamleshkhunti: ESSENCE Trial @NEJM Significant benefits of semaglutide in people with MASH and moderate or advanced liver fibrosis,…
RT @kamleshkhunti: ESSENCE Trial @NEJM Significant benefits of semaglutide in people with MASH and moderate or advanced liver fibrosis,…
RT @kamleshkhunti: ESSENCE Trial @NEJM Significant benefits of semaglutide in people with MASH and moderate or advanced liver fibrosis,…
RT @kamleshkhunti: ESSENCE Trial @NEJM Significant benefits of semaglutide in people with MASH and moderate or advanced liver fibrosis,…
ESSENCE Trial @NEJM Significant benefits of semaglutide in people with MASH and moderate or advanced liver fibrosis, Improved liver histologic results https://t.co/i4ZmWFhaDW https://t.co/PIPqwBBeew
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE trial) https://t.co/8…
RT @NEJM: Original Article: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE trial) https://t.co/8…
Link: https://t.co/T4Skn5V4qh
In patients with #MASH and moderate or advanced liver fibrosis, once-weekly #semaglutide at a dose of 2.4 mg improved liver histologic results.
RT @EARL_med_tw:
RT @EARL_med_tw:
New @nejm.org - Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis www.nejm.org/doi/full/10.... #Liversky #Medsky
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis www.nejm.org/doi/full/10....
EE
AB
JP
JY
E
VN
SS
AA
聡
EM